Robert Díaz Beveridge
0000-0003-3719-7014
Publication & Citation Trends
Publications
0 total
IMMUNOSARC II Master Trial: Phase II Study of Sunitinib and Nivolumab in Clear Cell Sarcoma Cohort
Cited by 0
Semantic Scholar
Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-line treatment for patients with Undifferentiated Pleomorphic Sarcoma.
Cited by 0
Semantic Scholar
Phase II of sunitinib plus nivolumab in extraskeletal myxoid chondrosarcoma: Results from the GEIS, ISG, and UCL IMMUNOSARC II Study.
Cited by 1
Semantic Scholar
Dermatological Toxicities of Tebentafusp, a New Bispecific Drug: Case Series and Literature Review
Cited by 1
Semantic Scholar
Real-life evidence of encorafenib plus binimetinib in patients with unresectable advanced or metastatic BRAFV600-mutant melanoma in Spain: the BECARE (GEM-2002) trial OA
Cited by 3
Semantic Scholar
Encorafenib and binimetinib followed by radiotherapy for patients with BRAFV600-mutant melanoma and brain metastases (E-BRAIN/GEM1802 phase II study)
Cited by 12
Semantic Scholar
Pharmacogenetics of Neoadjuvant MAP Chemotherapy in Localized Osteosarcoma: A Study Based on Data from the GEIS-33 Protocol OA
Cited by 4
Semantic Scholar
Research Topics
Sarcoma Diagnosis and Treatment
(34)
Vascular Tumors and Angiosarcomas
(13)
Cardiac tumors and thrombi
(10)
Pancreatic and Hepatic Oncology Research
(8)
Hepatocellular Carcinoma Treatment and Prognosis
(7)
Affiliations
McKesson (United States)
Hospital General Universitario Gregorio Marañón
Hospital Universitari i Politècnic La Fe
Pathways Behavioral Services
Leitat Technological Center